破裂性胸主动脉疾病腔内治疗后的生存率:来自全球登记研究的结果
本研究基于全球主动脉腔内治疗登记研究(GREAT),评估Conformable GORE TAG和GORE TAG胸主动脉支架治疗破裂性胸主动脉综合征的结局。共40例患者接受治疗,技术成功率100%,30天死亡率为10.0%,1年免于器械相关再干预率为87.1%,1年全因生存率为65.0%。结论认为这些支架是治疗破裂性胸主动脉疾病的有效方法,但可能需要主动脉分支血管的覆盖或血运重建。
要点
- 技术成功率100%,无术中死亡和转开放手术。
- 30天死亡率为10.0%,早期再干预率17.5%。
- 1年免于器械相关再干预率为87.1%,1年全因生存率为65.0%。
核心结论
- Conformable GORE TAG和GORE TAG胸主动脉支架为破裂性胸主动脉疾病提供了有效的治疗。
- 可能需要辅助性覆盖或血运重建主动脉分支血管。
- 需要更长的随访和更大规模的研究来确定修复的耐久性。
研究设计与样本
- 前瞻性观察性多中心队列登记研究(全球主动脉腔内治疗登记研究)。
- 纳入2010年12月至2016年10月间来自114个国际中心的5018例患者。
- 筛选出至少有一种破裂性胸主动脉疾病(降主动脉瘤破裂、胸腹主动脉瘤破裂、降主动脉夹层破裂、主动脉弓动脉瘤破裂)的患者。
- 最终分析40例接受GORE胸主动脉支架治疗的破裂性胸主动脉疾病患者。
主要发现
- 40例患者中男性占62.5%,平均年龄67.5±14.1岁。
- 技术成功40/40例(100%),无术中死亡,无中转开放手术。
- 12例(30.0%)需要干预主动脉分支血管(4例覆盖,5例手术去分支,1例支架,6例烟囱技术)。
- 30天死亡4例(10.0%),早期再干预(≤30天)7例(17.5%),其中5例与器械相关;共5例内漏,均需再干预。
临床怎么用
- 对于破裂性胸主动脉疾病,可考虑使用Conformable GORE TAG或GORE TAG胸主动脉支架进行腔内治疗。
- 应准备处理主动脉分支血管的覆盖或血运重建,可能需要辅助技术如烟囱技术或手术去分支。
- 术后需密切监测并计划再干预,因为早期再干预率较高(17.5%)。
局限性
- 样本量小(仅40例患者)。
- 随访时间相对较短(中位14.7个月)。
- 需要更长的随访和更大规模的研究来确定修复的耐久性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Global Registry for Endovascular Aortic Treatment is a prospective observational multicenter cohort registry of all Gore aortic endografts for a variety of aortic pathologies. The purpose of this study was to evaluate the outcome of the Conformable GORE TAG Thoracic Endoprosthesis and GORE TAG Thoracic Endoprosthesis devices for ruptured thoracic aortic syndromes. METHODS: Between December 2010 and October 2016, a total of 5018 patients were enrolled from 114 international sites in this registry. The database was queried for patients with at least one of the following pathologies: descending thoracic aortic aneurysm with rupture, thoracoabdominal aortic aneurysm rupture, descending aortic dissection rupture, and aortic arch aneurysm rupture. Patient demographics, operative details, and clinical outcomes were analyzed. RESULTS: A total of 40 patients were treated with a ruptured thoracic aortic disease (62.5% male; mean age, 67.5 ± 14.1 years). Nineteen patients were treated for descending thoracic aneurysm rupture, 9 for thoracoabdominal aneurysm rupture, 7 for descending aortic dissection rupture, and 5 for aortic arch aneurysm rupture. Technical success was achieved in 40 of 40 patients (100%). There were no intraoperative mortalities and no conversions to an open procedure. A total of 12 patients (30.0%) required intervention for involvement of at least one aortic branch vessel (4 covered, 5 surgically debranched, 1 stented, and 6 chimney technique). The 30-day mortality was four patients (10.0%). Early reintervention (≤30 days) was required in seven patients (17.5%), five of which were device related. There was a total of five endoleaks and all five required a reintervention. The median follow-up duration was 14.7 months (range, 1-57 months). Freedom from device-related intervention at 1 year was 87.1% (95% confidence interval, [CI], 0.716-0.944), at 2 years was 81.3% (95% CI 0.607-0.917) and at 3 years was 73.1% (95% CI, 0.47-0.878). Freedom from all-cause mortality at 1 year was 65.0% (95% CI, 0.474-0.780), at 2 years was 61.2% (95% CI, 0.431-0.751), and at 3 years was 56.1% (95% CI, 0.369-0.715). CONCLUSIONS: The Conformable GORE TAG Thoracic Endoprosthesis and GORE TAG Thoracic Endoprosthesis thoracic endografts provide an effective treatment for ruptured thoracic aortic diseases. Adjunctive coverage or revascularization of an aortic branch vessel may be necessary. Longer follow-up and larger studies are needed to determine durability of these repairs.
引用
- Walsh K, O'Connor DJ, Weaver F, et al. Survival after endovascular therapy in patients with ruptured thoracic aortic diseases: Results from the Global Registry for Endovascular Aortic Treatment Registry. J Vasc Surg. 2020. PMID: 32278574. doi:10.1016/j.jvs.2020.02.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。